Chardan Capital Reiterates “Buy” Rating for Immuneering (NASDAQ:IMRX)
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They presently have a $13.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 369.31% from the stock’s previous close. IMRX has been the topic […]
Immuneering (NASDAQ:IMRX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They presently have a $13.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 369.31% from the stock’s previous close. IMRX has been the topic […]
